Detalles de la búsqueda
1.
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial.
Eur J Cancer
; 199: 113531, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38271746
2.
From Co-Stimulation to Co-Inhibition: A Continuum of Immunotherapy Care Toward Long-Term Survival in Melanoma.
Onco Targets Ther
; 16: 227-232, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37041860
3.
Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial.
Nat Commun
; 14(1): 5914, 2023 09 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-37739939
4.
Corrigendum to "Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial" [Eur J Cancer 199 (2024) 113531].
Eur J Cancer
; 202: 113981, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38461074
Resultados
1 -
4
de 4
1
Próxima >
>>